ArticleNutrients2025
The Effect of a Four-Month Low-Carbohydrate Diet on Visceral Adipose Tissue in Obese Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPrevious studies have shown a relationship between Visceral Adipose Tissue (VAT) and Hepatic Fat Content (HFC), and increases in HFC are linked to metabolic abnormalities similar to those associated with elevated VAT. Several short-term and long-term studies have supported these findings. Lifestyle interventions remain the cornerstone of treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), although the ideal dietary regimen is still under debate.
methodsData on 2040 patients were extracted from the Clinical Nutrition Unit database between 2017 and 2019. Of these, 474 subjects with MASLD and Body Mass Index (BMI) ≥ 35 kg/m
resultsOur study demonstrates the significant efficacy of StD in reducing VAT in MASLD patients with moderate hepatic steatosis. In subjects with severe steatosis, there is no statistically significant response to dietary intervention. This may be attributed to several irreversible molecular mechanisms that fundamentally alter the hepatic microenvironment and limit the liver's capacity for regeneration and metabolic recovery.
conclusionsImprovements were largely confined to patients with moderate MASLD, with limited benefit in severe disease. Although dietary intervention remains the cornerstone of MASLD management, patients with severe steatosis should be informed about the potential limited resolution of steatosis, even with optimal metabolic control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.